Clinical Trials Logo

Gastric Cancer clinical trials

View clinical trials related to Gastric Cancer.

Filter by:

NCT ID: NCT04878783 Active, not recruiting - Gastric Cancer Clinical Trials

Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG

Start date: December 20, 2019
Phase:
Study type: Observational

The aim of this study is to develop a CT scan-based radiomics predictive model about tumor regression grade (TRG) in patients with esophago-gastric junction (EGJ) ang gastric cancer undergoing perioperative chemotherapy. The molecular expression of the neoplasms will be evaluated to assess its association with the TRG and the radiomic features.

NCT ID: NCT04842916 Active, not recruiting - Gastric Cancer Clinical Trials

InteGRAtive Analysis of tuMor, Microenvironment, immunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer

GRAMMY
Start date: September 22, 2020
Phase:
Study type: Observational

Multicentric, exploratory, non-pharmacologic, retrospective/prospective, translational study aiming to identify the molecular, cellular and psychological-sociological variables predictive of response to chemotherapy in gastric cancer patients.

NCT ID: NCT04798781 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

Start date: July 28, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on progression-free survival.

NCT ID: NCT04772989 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

ARC-12
Start date: March 19, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

NCT ID: NCT04661150 Active, not recruiting - Gastric Cancer Clinical Trials

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Start date: March 12, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ.

NCT ID: NCT04611997 Active, not recruiting - Gastric Cancer Clinical Trials

IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy

Start date: November 16, 2020
Phase: Phase 3
Study type: Interventional

Patients with locally advanced gastric adenocarcinoma (cT2-4a N-/+ M0) were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in guiding laparoscopic D2 lymph node dissection for gastric cancer after neoadjuvant chemotherapy by comparing injection ICG group and non-injection ICG group

NCT ID: NCT04593615 Active, not recruiting - Gastric Cancer Clinical Trials

Indocyanine Green Tracer Using in Laparoscopic Radical Gastrectomy for Locally Advanced Gastric Cancer

CLASS-11
Start date: November 10, 2020
Phase: N/A
Study type: Interventional

Patients with locally advanced gastric adenocarcinoma (CT2-4a N0/+ M0) were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in guiding laparoscopic D2 lymph node dissection for gastric cancer by comparing injection ICG group and non-injection ICG group.

NCT ID: NCT04579757 Active, not recruiting - Colorectal Cancer Clinical Trials

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Start date: March 5, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).

NCT ID: NCT04513223 Active, not recruiting - Colorectal Cancer Clinical Trials

A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors

Start date: March 30, 2021
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.

NCT ID: NCT04454476 Active, not recruiting - Gastric Cancer Clinical Trials

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

Start date: November 9, 2022
Phase: Phase 1
Study type: Interventional

This is a study of the safety and effectiveness of Trametinib treatment in patients who have received successful endoscopic submucosal resection of a Stage I gastric cancer.